Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance-Reference-Cited by-同舟云学术

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Published:2018-06-11 Issue:23 Volume:24 Page:5841-5849
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Turner David C.,Kondic Anna G.,Anderson Keaven M.,Robinson Andrew G.,Garon Edward B.,Riess Jonathan Wesley,Jain Lokesh,Mayawala Kapil,Kang Jiannan,Ebbinghaus Scot W.,Sinha Vikram,de Alwis Dinesh P.,Stone Julie A.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of prognostic nutritional index as prognostic biomarkers in patients with lymphoma: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-09-01

2. Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma;Clinical Pharmacology & Therapeutics;2024-07-22

3. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059;Clinical Pharmacokinetics;2024-06-22

4. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

5. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study;International Journal of Clinical Oncology;2024-06-04